Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins

Experimental Hematology

Volumn 41, Issue 8, 2013, Pages 675-686

  Tomic, Jelena ^a,b,c   McCaw, Lindsay ^a   Li, Youjun ^a   Hough, Margaret R ^a,b   Ben David, Yaacov ^a,b   Moffat, Jason ^c   Spaner, David E ^a,b,d  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; N ACETYLGLUCOSAMINE; O LINKED BETA N ACETYLGLUCOSAMINE; RESVERATROL; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR VOLUME;

3T3 CELLS; ACETYLGLUCOSAMINE; ANIMALS; DRUG ANTAGONISM; HUMANS; INTERFERONS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PROTEINS; STILBENES;

MUS;

EID: 84880746717     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.004     Document Type: Article

References (33)

1. Astsaturov I., Petrella T., Bagriacik E.U., et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 2003, 9:4347-4355.
2. Langenmayer I., Nerl C., Knauf W., et al. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br J Haematol 1996, 94:362-369.
3. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311.
4. Tomic J., Lichty B., Spaner D.E. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011, 117:2668-2680.
5. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
6. Shi Y., Tomic J., Wen F., et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia 2010, 24:1588-1598.
7. Slawson C., Hart G.W. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer 2011, 11:678-684.
8. Yehezkel G., Cohen L., Kliger A., Manor E., Khalaila I. O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-D-glucosaminidase silencing on cell phenotype and transcriptome. JBiol Chem 2012, 287:28755-28769.
9. Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K., Reginato M.J. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 2012, 287:11070-11081.
10. Gill N., Deacon P.M., Lichty B., Mossman K.L., Ashkar A.A. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol 2006, 80:9943-9950.
11. Yuzwa S.A., Macauley M.S., Heinonen J.E., et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau invivo. Nat Chem Biol 2008, 4:483-490.
12. Gross B.J., Kraybill B.C., Walker S. Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc 2005, 127:14588-14599.
13. Shaked Y., Cervi D., Neuman M., et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood 2005, 105:4500-4507.
14. Usenko T., Li Y.J., Haeri M., et al. Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. Blood 2009, 114:1831-1841.
15. Lee C.R., Cervi D., Truong A.H., Li Y.J., Sarkar A., Ben-David Y. Friend virus-induced erythroleukemias: a unique and well-defined mouse model for the development of leukemia. Anticancer Res 2003, 23:2159-2166.
16. Shibuya T., Mak T.W. Isolation and induction of erythroleukemic cell lines with properties of erythroid progenitor burst-forming cell (BFU-E) and erythroid precursor cell (CFU-E). Proc Natl Acad Sci U S A 1983, 80:3721-3725.
17. Hallek M., Cheson B.D., Catovsky D., et al. International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia. Blood 2008, 111:5446-5456.
18. Spaner D.E., Lee E., Shi Y., et al. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 2013, 27:1090-1099.
19. Holt G.D., Snow C.M., Senior A., Haltiwanger R.S., Gerace L., Hart G.W. Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine. J Cell Biol 1987, 104:1157-1164.
20. Moffat J., Grueneberg D.A., Yang X., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
21. Aluyen J.K., Ton Q.N., Tran T., Yang A.E., Gottlieb H.B., Bellanger R.A. Resveratrol: potential as anticancer agent. J Diet Suppl 2012, 9:45-56.
22. Bertilaccio M.T., Scielzo C., Simonetti G., et al. Xenograft models of chronic lymphocytic leukemia: Problems, pitfalls and future directions. Leukemia 2013, 27:534-540.
23. Hart G.W., Slawson C., Ramirez-Correa G., Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu Rev Biochem 2011, 80:825-858.
24. Shay J.W., Wright W.E. Tissue culture as a hostile environment: identifying conditions for breast cancer progression studies. Cancer Cell 2007, 12:100-101.
25. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
26. Grigorian A., Lee S.U., Tian W., et al. Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem 2007, 282:20027-20035.
27. Levy C., Frecha C., Costa C., et al. Lentiviral vectors and transduction of human cancer B cells. Blood 2010, 116:498-500.
28. Hart G., Housley M., Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007, 446:1017-1022.
29. Zhang F., Su K., Yang X., Bowe D., Paterson A., Kudlow J. O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 2003, 115:715-725.
30. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005, 280:37377-37382.
31. Su L., David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000, 275:12661-12666.
32. Park S.J., Ahmad F., Philp A., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
33. Howitz K.T., Bitterman K.J., Cohen H.Y., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.